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Abstract  
Objective: Hypercalcemia as the consequence of an excessive bone resorption is a common 
complication in patients with cancer. The aim of the study was to analyze the prevalence of 
hypercalcemia in patients with tumor-induced osteolysis starting therapy with bisphosphonates.  
Methods: The questionnaire-based survey (data collected during three consecutive examinations 
within a 3-month period) was conducted among 1,450 patients treated with bisphosphonates for 
tumor-induced osteolysis.  
Results: Hypercalcemia was found in 8.7% respondents starting the treatment with 
bisphosphonates. The most common cause of malignancy-associated hypercalcemia was prostate 
cancer, multiple myeloma and breast cancer. On the other hand, hypercalcemia was the most 
prevalent among patients with multiple myeloma, metastatic cancer of an unknown primary origin 
and bladder cancer. Metastases were reported in 342 patients, while pathological fractures in 37. 
The normalization of calcium level was obtained in 91.4% of the patients treated with 
bisphosphonates, mostly clodronate. During the bisphosphonate therapy, pathological fractures 
occurred in 4.6% of patients and the percentage of the patients reporting bone pain decreased from 
79.9% to 30.9%.  
Conclusion: Multiple myeloma, prostate and breast cancer are the most common causes of 
hypercalcemia of malignancy in patients with tumor-induced osteolysis starting therapy with 
bisphosphonates. 
 
 
 
 
 
 
Introduction 
 Hypercalcemia resulting from an excessive 
bone resorption is a common complication in patients 
with advanced cancer, and the malignancy is the most 
common cause of hypercalcemia in clinical practice 
(approximately 70% of cases) [1]. There are three 
major cancers particularly contributing to the 
development of hypercalcemia: multiple myeloma 
(MM) (in approximately 20 - 40% of patients), T-cell 
lymphoma (about 50% of patients) and breast cancer 
(in 20-40% of cases) [2-4]. The primary mechanism of 
hypercalcemia in the patients with cancer is an 
increased bone resorption resulting from tumor 
secretion of cytokines, PTH-related peptide (PTHrp) 
and calcitriol [5]. Bone pain is the most common 
clinical sign of increased tumor-induced osteolysis, 
reported by approximately 60% of patients [6]. 
The use of bisphosphonates is the treatment 
of choice in patients with tumor-induced osteolytic 
hypercalcemia. The drugs bind to the surface of 
hydroxyapatite, inhibit osteoclast-mediated bone 
osteolysis (thus decreasing calcium release and 
formation), inhibit maturation of osteoclasts (by 
inducing their apoptosis), reduce the loss of bone 
mineral mass and the risk of bone fractures and have 
an analgesic effect [7-9]. 
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The aim of the study was to analyze the 
prevalence of hypercalcemia in patients with tumor-
induced osteolysis starting therapy with 
bisphosphonates. 
 
Materials and Methods 
 The study, performed in the years 2009-2010, 
consists of a survey involving 172 physicians who 
agreed to participate in the study of about 300 eligible 
working in oncologic and pain management outpatient 
clinics throughout the country. Specialists were 
recruited by medical representatives who distributed 
the questionnaires, being obliged not to advertise any 
specific bisphosphonate during the visit. The 
participating physicians were asked to recruit among 
their patients diagnosed with cancer the ones treated 
with bisphosphonates due to tumor-induced osteolysis 
established on the basis of the latest available X-ray 
imaging with serum calcium level examined prior to 
the initiation of the therapy with primary 
hyperparathyroidism being the only exclusion 
criterion. The physician filling the questionnaire 
declared that have complete insight into medical 
records of the patient. This declaration was not 
verified. 
The approval of the ethical committee was not 
required as the questionnaire-based survey was 
based on a routine follow up of clinical patients, no 
patient identification was recorded and thus the study 
did not fulfill the criterion of a medical experiment. 
The participating physicians were asked to 
complete the 3-part questionnaire on the basis of 
medical records (excluding the patients’ personal 
details), during three consecutive examinations within 
a 3-month period. The first part of the questionnaire 
(completed during the first examination) included 
demographic data (sex, age, place of residence) and 
information about: the type of cancer, the clinical 
course of the disease before the implementation of 
bisphosphonate therapy (tumor-induced osteolysis, 
pathological fractures due to metastasis, 
hypercalcemia of malignancy), the duration of the 
treatment, the dose and type of bisphosphonate used, 
the serum calcium level at the time when 
hypercalcemia was diagnosed, the occurrence of 
cancer-related bone pain, pathological fractures that 
occurred during bisphosphonate treatment and the 
history of any previous treatment with intravenous 
bisphosphonates. Serum total calcium level over 10.5 
mg/dl was defined as hypercalcemia. Additionally, the 
participating physicians were asked to check if any 
previous bisphosphonate treatment resulted in the 
normalization of calcium level. The second and third 
part of the questionnaire were completed during a 3-
month follow-up period. This time the participating 
physicians were asked to record the data related to 
the therapeutic effect of the applied treatment, e.g.: 
the occurrence of newly diagnosed pathologic bone 
fractures or hypercalcemia, the persistence of 
hypercalcemia, the occurrence of self-reported bone 
pain and the initiation of the treatment with calcium 
and vitamin D. The presence of bone pain defined as 
a tenderness of the skeleton, worsening on palpation, 
with characteristic enhancement during the night, was 
assessed on the basis on patients' complaints during 
the last week prior to examination. 
Bisphosphonates were mainly used orally. 
Only in 37 hypercalcemic (26.6 %) and 204 
normocalcemic (15.3%) patients bisphosphonates 
were initially used intravenously. The compliance to 
orally given bisphosphonates was measured by the 
frequency of missing drug doses between consecutive 
examinations reported by patients or patients’ 
guardian.  
Of the planned recruitment of 5,000 patients 
diagnosed with tumor-induced osteolysis treated with 
bisphosphonates, only 1,495 subjects (29.9% 
effectiveness) were enrolled due to lower than initially 
planned effectiveness of participating physicians 
recruitment.15 subjects treated with bisphosphonates 
for osteoporosis were excluded from the analysis.  
 All data are expressed as percentages or 
means with standard deviations. The analyses were 
performed using the STATISTICA 10.0 PL (StatSoft 
Polska, Kraków, Poland) and MedCalc v. 14.4.4.0 
(Software, Mariakerke, Belgium) software. The χ
2
 test 
and the logistic regression analysis were applied for 
the calculation of a relative risk (RR) and their 95% 
confidence intervals (CI). A p value less than 0.05 was 
considered statistically significant. 
 
Results 
Characteristic of the study group 
The detailed characteristics of the study group 
are shown in Table 1. Hypercalcemia of malignancy 
was diagnosed in 129 (8.7%) of 1480 respondents (in 
32.6% of patients with multiple myeloma, 23.1% of 
patients with metastatic cancer of unknown primary 
origin and in 16.7% of patients with bladder cancer). 
The most common cause of hypercalcemia in the 
group was prostate cancer (38.0%), multiple myeloma 
(22.5%) and breast cancer (20.9%) – Figure 1. The 
mean serum calcium level in the hypercalcemic 
patients at the time of the diagnosis was 3.06 (2.97-
3.15) mmol/l.  
Metastases were reported in 342, while 
pathological fractures in 37 patients (23.1% and 2.5% 
of the cases respectively). Pathological bone fractures 
were more frequent among the patients with 
metastatic disease  (9.8% vs. 2.2% in the patients 
without metastasis, p<0.001). Bone pain was reported 
by 79.9% of the patients with cancer, more frequently 
in the patients with metastases (87.8% vs. 77.5% 
without metastasis), but with a similar frequency in 
patients with and without a history of bone fractures 
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and in those with and without hypercalcemia. 
Hypercalcemia was equally frequent in the patients 
with and without diagnosed metastases 7.1% vs. 
7.6% (after exclusion of the patients with multiple 
myeloma) and unrelated to bone pain.  
 
Table 1: Characteristics of study group (n=1,480). 
Age [n ,(%)] 
  
18-40 years  13 (0.9) 
41-60 years  459 (31.0) 
>60 years 1,008 (68.1) 
Sex [men (%)] 892 (60.3) 
Malignant disease [n]  
Prostate cancer 613 
Breast cancer 468 
Bronchial cancer 90 
Multiple myeloma 89 
Renal cancer 81 
Colon cancer 50 
Bladder cancer 18 
Cervical / endometrial cancer 16 
Disseminated cancer of unknown primary origin 13 
Others 42 
Period of treatment due to cancer [months] 34 ± 30 
Duration of bisphosphonate treatment [months] 13 ± 13 
Type of bisphosphonate [n,(%)]  
Alendronate 12 (0.8) 
Clodronate 1,421 (96.0) 
Ibandronate 2 (0.1) 
Unspecified 45 (3.1) 
Hypercalcemia [n,(%)] 129 (8.7) 
Diagnosed metastases [n, (%)]  342 (23.1) 
Pathological fractures [n, (%)] 37 (2.5) 
Concomitant osteoporosis [n,( %)] 19 (1.3) 
 
 
 The mean duration of the bisphosphonate 
therapy was 13 ± 13 months, with a mean treatment 
for cancer of at 34 ± 30 months. Clodronate was the 
most commonly used bisphosphonate (96.0%). Its 
dose used in the patients without hypercalcemia was 
1422 mg (1324-1519), and was significantly lower 
than the dose used because of hypercalcemia 
1504mg (1445-1563) (p<0.001). 
 
Figure 1: The prevalence of hypercalcemia according to the type of 
cancer. 
 
Effectiveness of the treatment 
 Two consecutive examinations were 
performed on 1477 and 1476 patients.  The 
compliance with bisphosphonate therapy was 99.4%. 
The normal range of calcium level was reached in 127 
out of 139 hypercalcemic patients (91.4% of the 
patients treated with bisphosphonates). In 37 
hypercalcemic (26.6%) and 204 normocalcemic 
(15.3%) patients bisphosphonates were initially used 
intravenously. During the follow-up, bone fracture 
occurred in 67 patients (4.6%), despite the treatment 
with bisphosphonates in 7 patients with hypercalcemia 
(5.0%) and 60 without hypercalcemia (4.5%), in 6.3% 
of the patients without any previous pathologic bone 
fractures and 4.8% without any previous fractures.  
During the follow-up, the number of patients 
reporting bone pain decreased from 79.9% to 30.9% 
(p <0.001). Bone pain remained more common in the 
patients with a pathological fracture (50.3% vs. 28.2%, 
p <0.001), RR = 2.24 (1.73-2.92). 
 
Discussion  
Hypercalcemia is relatively common in 
patients with cancer. Osteolytic metastases account 
for approximately 20 % of cases of hypercalcemia of 
malignancy [10]. The induction of local osteolysis by 
tumor cells is common with some solid tumors (eg. 
breast cancer) that metastasize to bone and with 
multiple myeloma [11-12]. The bone destruction 
observed in osteolytic metastases is primarily 
mediated by osteoclasts, but not by a direct effect of 
tumor cells [13]. The present study was not designed 
to assess the prevalence of tumor-induced osteolysis 
and hypercalcemia of malignancy, but only the 
incidence of bone complications found in the patients 
treated with oral bisphosphonates. Thus, on the basis 
of this study one can only estimate the incidence of 
hypercalcemia in the patients with tumor-induced 
osteolysis. Multiple myeloma (MM) was found to be 
the most common cause for hypercalcemia in the 
analyzed group of the patients diagnosed with cancer 
(32.6%). Our observation is consistent with the results 
of another study indicating the presence of this 
pathology in 28% of the patients diagnosed with MM 
[14]. Tumor-induced osteolytic hypercalcemia is often 
present in the patients with metastatic cancer of 
unknown primary origin (23.1%), thus reflecting its 
advanced clinical stage. Somewhat surprising is the 
high percentage of the patients with malignant 
hypercalcemia in the group of patients with bladder 
cancer (up to 16.7%) which was not a common cause 
of hypercalcemia in our study group. Previously 
published studies did not indicate such a high 
incidence of hypercalcaemia in the patients with 
bladder cancer. According to the Japanese authors, 
the incidence was approximately 1.9% [15]. The 
reason for these discrepancies is probably a relatively 
late occurrence of osteolytic metastases of bladder 
cancer to bone.  
Hypercalcemia of malignancy caused by 
osteolysis was also observed in the patients with 
renal, cervix / uterus, prostate, breast, bronchial and 
colon cancers (Figure 1). Bisphosphonates are unique 
in the treatment of metastatic bone disease as it is a 
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bone-targeted therapy. Its effectiveness in lowering 
the calcium level is not easy to evaluate, as the 
normalization of calcaemia can only be temporary. In 
our study, bisphosphonates (clodronate mainly) 
decreased the calcium serum level in 91.4% of cases. 
This result is in consistence with the results of meta-
analysis performed by Sanders et al. where the 
efficacy was evaluated to be over 70% [16]. 
Bisphosphonates are also supposed to prevent the 
occurrence of hypercalcemia in the patients with 
tumor-induced osteolysis. In the patients with MM, 
Laakso et al., found clodronate (at a dose of 2.4 
g/day) to be protective against hypercalcemia, as well 
as against the vertebral and non-vertebral fractures 
[17]. Bisphosphonates have also been effective in the 
treatment of bone metastases from other solid tumors, 
including breast, lung, prostate, kidney and colorectal 
[18]. In the present study, hypercalcemia was reported 
only in 0.8% of patients during the treatment with 
clodronate. Additionally, very early studies have 
suggested that the use of clodronate may be 
protective against fractures both in patients with 
breast cancer and in patients with multiple myeloma 
[18, 19]. These observations were finally proved, 
however intravenous therapy seemed to be more 
effective than the oral one. According to the meta-
analysis performed by Pavlakis et al. zolendronic acid, 
pamidronate and ibandronate reduced the bone 
complications in patients with breast cancer by 41%, 
33% and 18%, respectively [20]. Recently published 
data by Terpos et al. showed a similar protective 
effect of bisphosphonates in patients with MM [21]. 
The natures of our study, without a placebo-treated 
control group, preclude the assessment of the bone-
protective effect of bisphosphonate therapy. In our 
study, fractures were recorded in 4.6% of the patients 
treated with bisphosphonates during the follow-up. 
One of the most common complaints made by 
the patients with skeletal metastases is intractable 
bone pain. It is postulated that the factors produced by 
tumor cells, as well as the molecules released by 
bone remodeling, stimulate pain receptors in bone 
[22]. According to Clines et al bisphosphonates can 
reduce the intensity of pain, stimulating the molecules 
in the microenvironment surrounding metastatic tumor 
cells [5]. There are some other data that complement 
our knowledge about a possible anti-tumor activity of 
bishosphonates. They were found to have direct 
effects on tumor cells aiding the reduction of tumor 
growth and its invasiveness, as well as helping induce 
apoptosis [23-25]. Bisphosphonates may also reduce 
the adhesion of tumor cells to bone and inhibit 
angiogenesis [26-27]. 
The evaluation of bone pain in our study 
group showed a decrease in the number of patients 
reporting this problem from 79.9% to 30.9%.  It is 
consistent with the result of other authors, who 
showed an analgesic effect of bisphosphonates, in the 
patients with both MM and prostate cancer [28-29]. 
However, it must be pointed out that the effectiveness 
of bisphosphonate is limited when the progression of 
cancers (increased tumor-induced osteolysis and 
metastases) is observed. In our study, bone pain 
remained more common in patients with pathological 
fractures.   
Our study has several limitations, mostly 
related to the study design and the enrollment of a 
highly heterogeneous group of patients. The power of 
statistical analysis was reduced by the lower than 
initially planned number of participating physicians. 
The incidence of hypercalcemia was reported by 
physicians and not controlled in a central laboratory. 
Moreover, we cannot exclude the selection bias 
related to the non-included patients with a short life 
expectancy. Thus our study does not fit in well with 
the ongoing debate whether bisphosphonates for 
tumor-induced osteolysis should be administered 
early in the course of the disease and if they have a 
beneficial effect on survival.  The analysis of the effect 
of bisphosphonates on bone pain is limited as the 
treatment with analgesics was not recorded. 
Therefore, we cannot exclude that in many cases the 
escalation of analgesics was the cause for the pain 
relief, as the data concerning this medication (non-
steroid anti inflammatory drug, opioids and co-
analgesics) were not collected.    
Despite all these limitations our study reflects 
the prevalence of hypercalcemia in patients with  
tumor-induced osteolysis not restricted to selected 
type of malignant disease.   
In a conclusion, multiple myeloma, prostate 
and breast cancer are the most common causes of 
hypercalcemia of malignancy in patients with tumor-
induced osteolysis starting therapy with 
bisphosphonates. 
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